April 12, 2021

Neutralization of SARS-CoV-2 Variants by Convalescent and Vaccinated Serum

Category: Article Summary

Topic: Testing and Treatment

Keywords (Tags): antibodies, treatment, vaccine, variant

• [Pre-print, not peer-reviewed] Sera from convalescent individuals (n = 44) and individuals who received the Pfizer-BioNTech vaccine (n = 51) showed reduced neutralization activity against the SARS-CoV-2 B.1.1.7 and B.1.351 variants. Among vaccinated individuals, the geometric mean 50% receptor binding domain (RBD) antibody concentration was 1.3-fold lower for the B.1.1.7 variant and 1.4-fold lower for the B.1.351 variant. Age was negatively correlated with neutralization among vaccinated individuals, and levels of variant-specific RBD antibodies were proportional to neutralizing activity. 

Bates et al. (Apr 9, 2021). Neutralization of SARS-CoV-2 Variants by Convalescent and Vaccinated Serum. Pre-print downloaded Apr 12 from https://doi.org/10.1101/2021.04.04.21254881